• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Army backs feasibility study for Teleflex’s RePlas freeze-dried plasma

Army backs feasibility study for Teleflex’s RePlas freeze-dried plasma

May 15, 2017 By Sarah Faulkner

TeleflexTeleflex (NYSE:TFX) said today that it launched the Phase I trial of its RePlas lyophilized fresh frozen plasma product being developed with the U.S. Army Medical Material Development Activity.

The freeze-dried plasma technique was 1st developed by Vascular Solutions, which was acquired for $1 billion by Teleflex in February.

The 24-patient study is designed to assess safety and tolerability of RePlas freeze-dried plasma. Healthy volunteers will receive increased doses of their own blood plasma that has been processed using the company’s proprietary lyophilization (freeze drying) and packaging techniques.

“We are pleased to be underway with the clinical study of this novel freeze-dried plasma product, which could have valuable applications in the treatment of military trauma as well as trauma care in a wide variety of other settings,” principal investigator Dr. Jose Cancelas said in prepared remarks.

The USAMMDA said that developing a commercially available source of freeze-dried plasma is a top priority, since early administration of plasma is an important step to limiting trauma mortality from uncontrolled bleeding.

In April 2014, Vascular Solutions inked a cooperative R&D program with Vascular Solutions. According to the deal, the USAMMDA provides will support the company’s regulatory and clinical work for RePlas and Vascular Solutions owns all intellectual property and commercial rights.

“We are honored to be working with the U.S. Army on this critical, life-saving product, and it is exciting for us to be entering the clinical development phase of this project 3 years after beginning the collaboration,” Steve Penegor, VP of biological development at Vascular Solutions, said. “The lyophilization of biologic materials is one of our core technical competencies, as we have demonstrated with several successful clinical and commercial endeavors, beginning more than a decade ago with our D-Stat Dry Hemostatic Bandage. Since entering into the development agreement with the U.S. Army in April of 2014, we have made significant strides, including the development of our commercial-scale production equipment in our new, dedicated biologics manufacturing facility.”

Filed Under: Blood Management, Clinical Trials, Wall Street Beat Tagged With: Teleflex

More recent news

  • Penumbra completes enrollment in pulmonary embolism trial
  • Zoll opens new facility in Rhode Island
  • FDA expands clearance for Inquis Medical’s Aventus thrombectomy system
  • SS Innovations completes first robotic cardiac surgery in the Americas
  • GI Windows wins FDA nod for magnet tech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy